On-site Pharmacist Implementation Trial In Residential Aged Care Homes in Urban, Regional, Rural and Remote (OPTIMISER3) Australia
Not Applicable
- Conditions
- Public HealthPublic Health - Health service research
- Registration Number
- ACTRN12624000827538
- Lead Sponsor
- niversity of Canberra
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Inclusion criteria for residential aged care homes:
- An accredited facility
- Located in a non-ACT area
- More than 20 beds and less than 150 beds
Inclusion criteria for residential aged care residents:
- Permanent resident in a facility that fits inclusion criteria
Exclusion Criteria
None
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A composite outcome of barriers and enablers to sustainable implementation of the on-site pharmacist in RACH model in regional, rural, remote, and non-ACT urban areas<br>[Interactive stakeholder workshops of group of between 5-10 participants held face to face or online with members of the research team, focus group discussion of between 5-10 participants held face to face or online with members of the research team. Interactive stakeholder workshop held pre-trial, On-site pharmacists will work in the role for 12 months and following the 12-month period stakeholders (i.e. aged care staff, on-site pharmacists, community pharmacy, GP, residents, family members/carers) will participate in a focus group. ]
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does on-site pharmacist implementation in ACTRN12624000827538 impact medication error rates in aged care?
What are the comparative effectiveness outcomes of ACTRN12624000827538 versus standard care in geriatric pharmacotherapy?
Which patient characteristics predict improved health outcomes from pharmacist-led interventions in ACTRN12624000827538?
What adverse drug events are monitored in ACTRN12624000827538 and how are they managed in aged care settings?
Are there similar pharmacist integration trials in Australian rural vs. urban residential aged care facilities?